This statement is what really interests me:
"expanded to enable increased data capture and provide additional insights to support Botanix’s broader dermatology platform. Some of the design changes include centralised review of investigator ratings and universal use of advanced Canfield imaging technology to support clinical assessments and patient tracking."
My thoughts are that BOT are going to use the Rosacea 1B trial to test some quality control ideas in terms of ensuring all the dermatologists involved are making reliable observations about patient progress. IMO this is more than just a Rosacea trial, it's also an attempt to elimintate the non-sense that happened during the Phase 2 acne trials before commencing Phase 3. Would I be wrong in reading between the lines and suggesting there may be some serious thought that the rogue vehicle results in Phase 2 Acne were the result of some very poor subjective observations by a dermatologist?
This statement is what really interests me:"expanded to enable...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.020(6.45%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 33.5¢ | 30.5¢ | $2.848M | 8.878M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24615 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 105525 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
33.0¢ |
Change
0.020 ( 6.73 %) |
||||
| Open | High | Low | Volume | ||
| 31.0¢ | 33.5¢ | 30.8¢ | 3931977 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| BOT (ASX) Chart |